OncoZenge AB (publ) (STO:ONCOZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.84
-0.25 (-4.11%)
Jan 21, 2026, 5:23 PM CET
0.17%
Market Cap77.02M
Revenue (ttm)2.78M
Net Income (ttm)-8.56M
Shares Out12.65M
EPS (ttm)-0.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume64,604
Average Volume33,471
Open5.85
Previous Close6.09
Day's Range5.63 - 6.14
52-Week Range3.72 - 10.28
Beta1.44
RSI41.92
Earnings DateFeb 18, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol ONCOZ
Full Company Profile

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial Statements